Evolving Therapeutic Options for Type 2 Diabetes Mellitus: An Overview

References

• . Oral hypoglycaemic drags. Br Med J. 1969;1(5647):829–831
   Google Scholar
• . US Department of Health and Human Services; US Food and Drag Administration; Center for Drag Evaluation and Research. Guidance for Industry: Diabetes Mellitus—Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guid-ances/ucm071627.pdf. December 2008. Accessed October 12, 2011
   Google Scholar
• . National Institutes of Health. Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC). http://report.nih.gov/rcdc/categories/. Accessed July 12, 2012
   Google Scholar
• . American Diabetes Association. American Diabetes Association to Testify for Increased Diabetes Funding, http://www.diabetes.org/for-media/2010/american-diabetes-association-3.html. Accessed July 16, 2012
   Google Scholar
• . Nathan DM, Buse JB, Davidson MB, ; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Vaisrab S. Serendipitous sulphonylureas. JAMA. 1972;219(10):1335
   Google Scholar
• . Stoner GD. Hyperosmolar hyperglycemic state. Am Fam Physician. 2005;71(9):1723–1730
   PubMed Web of Science ®Google Scholar
• . Pfeifer MA, Halter JB, Judzewitsch RG, . Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man. Diabetes Care. 1984;7( suppl 1):25–34
   Google Scholar
• . Hadden DR. Goat's rue—French lilac—Italian fitch—Spanish sainfoin: gallega officinalis and metformin: the Edinburgh connection. J R Coll Physicians Edinb. 2005;35(3):258–260
   Google Scholar
• . Rabinowitch IM. Observations on the use of synthalin in the treatment of diabetes mellitus. Can Med Assoc J. 1927;17(8):901–904
   Google Scholar
• . Wise PH, Chapman M, Thomas DW, Clarkson AR, Harding PE, Edwards JB. Phenformin and lactic acidosis. Br Med J. 1976;1(6001):70–72
   Google Scholar
• . UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet. 1998;352(9131):854–865
   PubMed Web of Science ®Google Scholar
• . Florez H, Luo J, Castillo—Florez S, . Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med. 2010;122(2):112–120
   PubMed Web of Science ®Google Scholar
• . Fujii N, Jessen N, Goodyear LJ. AMP-activated protein kinase and the regulation of glucose transport. Am J Physiol Endocrinol Metab. 2006;291(5): E867–E877
   Google Scholar
• . Gale EA. The discovery of type 1 diabetes. Diabetes. 2001;50(2):217–226
   Google Scholar
• . Yki—Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106–1118
   PubMed Web of Science ®Google Scholar
• . GlaxoSmithKline's Avandia® (rosiglitazone maleate) reaches 20 million prescription milestone [news release]. Philadelphia, PA: PR News-wire; November 7, 2002. http://www.prnewswire.com/news-releases/glaxosmithklines-avandiar-rosiglitazone-maleate-reaches-20-million-prescription-milestone-76702592.html. Accessed July 30, 2012
   Google Scholar
• . Rogue A, Spire C, Bran M, Claude N, Guillouzo A. Gene expression changes induced by PPAR gamma agonists in animal and human liver. PPAR Res. 2010;2010:325183
   PubMed Web of Science ®Google Scholar
• . Nesto RW, Bell D, Bonow RO, . Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation. 2003;108(23):2941–2948
   PubMed Web of Science ®Google Scholar
• . Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170(14):1191–1201
   PubMed Web of Science ®Google Scholar
• . Hurren KM, Taylor TN, Jaber LA. Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert. Diabetes Res Clin Pract. 2011;93(1):49–55
   Google Scholar
• . Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH. Thiazolidinedione drags and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation. 2010;121(16):1868–1877
   PubMed Web of Science ®Google Scholar
• . Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180–1188
   PubMed Web of Science ®Google Scholar
• . Lewis JD, Ferrara A, Peng T, . Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34(4):916–922
   PubMed Web of Science ®Google Scholar
• . FDA drag safety communication: update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer [safety announcement]. Silver Spring, MD: US Food and Drug Administration; June 15, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm. Accessed July 30, 2012
   Google Scholar
• . Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV Crit Rev Clin Lab Sci. 2003;40(3):209–294
   PubMed Web of Science ®Google Scholar
• . Lotfy M, Singh J, Kalasz H, Tekes K, Adeghate E. Medicinal chemistry and applications of incretins and DPP-4 inhibitors in the treatment of type 2 diabetes mellitus. Open Med Chem J. 2011;5( suppl 2):82–92
   PubMedGoogle Scholar
• . Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care. 2010;33(8):1859–1864
   PubMedGoogle Scholar
• . Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev. 2011;27(4):362–372
   PubMed Web of Science ®Google Scholar
• . Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2010;20(4):224–235
   PubMed Web of Science ®Google Scholar
• . Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause—Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26 (7):540–549
   PubMed Web of Science ®Google Scholar
• . Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011;13(1):7–18
   PubMed Web of Science ®Google Scholar
• . Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011;34(11):2474–2476
   PubMed Web of Science ®Google Scholar
• . Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012;344:el369
   Google Scholar
• . Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-l-yl)-7-but-2-ynyl-3-mefhyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008;325(1):175–182
   PubMed Web of Science ®Google Scholar
• . Tradjenta® (linagliptin) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2012; http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Tradjenta/Tradjenta.pdf. Accessed July 30, 2012
   Google Scholar
• . Onglyza® (saxagliptin) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011; http://packageinserts.bms.com/pi/pi_onglyza.pdf. Accessed July 29, 2012
   Google Scholar
• . Januvia® (sitagliptin) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2012. http://www.merck.eom/product/usa/pi_circulars/j/januvia/januviapi.pdf. Accessed July 29, 2012
   Google Scholar
• . Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27( suppl 3):57–64
   PubMed Web of Science ®Google Scholar
• . Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010; 95(1):34–42
   PubMed Web of Science ®Google Scholar
• . Hardman TC, Dubrey SW. Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diabetes Ther. 2011;2(3):133–145
   PubMedGoogle Scholar
• . Araki T, Hirayama M, Hiroi S, Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(3):271–278
   PubMed Web of Science ®Google Scholar
• . Kebede MA, Alquier T, Latour MG, Poitout V. Lipid receptors and islet function: therapeutic implications? Diabetes Obes Metab. 2009;11( suppl 4):10–20
   PubMed Web of Science ®Google Scholar
• . Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PR, Rorsman P. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J Pharmacol Exp Ther. 2012;340(2):483–489
   PubMed Web of Science ®Google Scholar
• . Lin DC, Zhang J, Zhuang R, . AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One. 2011;6(11):e27270
   PubMed Web of Science ®Google Scholar
• . Overton HA, Fyfe MC, Reynet C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol. 2008;153( suppl 1):S76–S81
   PubMed Web of Science ®Google Scholar
• . Lauffer L, Iakoubov R, Brubaker PL. GPR119: “double-dipping” for better glycemic control. Endocrinology. 2008;149(5):2035–2037
   Google Scholar
• . Yoshida S, Tanaka H, Oshima H, . AS1907417, a novel GPR119 agonist, as an insulinotropic and beta-cell preservative agent for the treatment of type 2 diabetes. Biochem Biophys Res Commun. 2010;400(4):745–751
   PubMed Web of Science ®Google Scholar
• . Burant CF, Viswanathan P, Marcinak J, . TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2012;379(9824):1403–1411
   PubMed Web of Science ®Google Scholar
• . Katz LB, Gambale JJ, Rothenberg PL, . Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes Obes Metab. 2012;14(8):709–716
   PubMedGoogle Scholar
• . Ginsberg HN, Elam MB, Lovato LC, ; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574
   PubMed Web of Science ®Google Scholar
• . Hansen BC, Tigno XT, Benardeau A, Meyer M, Sebokova E, Mizrahi J. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/Γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome. Cardiovasc Diabetol. 2011;10:7
   PubMedGoogle Scholar
• . Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009;374(9684):126–135
   PubMed Web of Science ®Google Scholar
• . Su H, He M, Li H, . Boc5, a non-peptidic glucagon-like peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice. PLoS One. 2008;3(8):e2892
   Google Scholar
• . Sando KR, Taylor J. Bromocriptine: its place in type 2 diabetes tx. J Fam Pract. 2011;60(11): E1–E5
   Google Scholar